Qing Zhu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Qing Zhu has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Lei Wang
School of Traditional Chinese Medicine, Guangdong Pharmaceutical University, Guangzhou, China
5 shared publications Yuhan Gan
School of Traditional Chinese Medicine, Guangdong Pharmaceutical University, Guangzhou, China
3 shared publicationsYuting Zeng
School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, China
3 shared publicationsJingyi Huang
Key Laboratory of Glucolipid Metabolic Disorder, Ministry of Education of China, Guangdong Pharmaceutical University, Guangzhou, China
2 shared publicationsShasha Li
Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, China
2 shared publicationsTianyi Xie
School of Traditional Chinese Medicine, Guangdong Pharmaceutical University, Guangzhou, China
2 shared publications
Latest Publications
- Open Access
- 15 July 2026
- Published by Wiley in Food Science & Nutrition
- Vol. 14 (7) , e72063
Oleanolic Acid Ameliorates Hepatic Lipid Metabolism and Autophagy in Type 2 Diabetic Mice via the STAT3 Signaling Pathway
Type 2 diabetes mellitus (T2DM) poses a major global health challenge due to its considerable disability and mortality rates. The complex etiology of T2DM involves hepatic steatosis and autophagy dysfunction. Previous research indicates that oleanolic acid (OA) ameliorates T2DM, with signal transducer and activator of transcription 3 (STAT3) serving as a crucial regulator in numerous cellular processes. Therefore, this study aims to explore whether the therapeutic effects of OA are associated with STAT3 activation and its potential role in hepatic lipid metabolism and autophagy in T2DM. T2DM was induced in mice by feeding a high‐fat diet followed by multiple low‐dose streptozotocin injections. OA notably lowered blood glucose and lipid levels, along with improvements in glucose tolerance and insulin sensitivity. Additionally, OA alleviated liver injury and steatosis. In T2DM mice, OA reduced hepatic protein and gene expression associated with fatty acid uptake/synthesis while enhancing those linked to fatty acid β‐oxidation. Moreover, OA modulated autophagy‐related proteins, as evidenced by increased p62 levels and decreased LC3‐II and Beclin‐1 levels. Molecular docking analysis predicted a potential interaction between OA and STAT3, and Western blot showed increased STAT3 phosphorylation at Y705 after OA treatment . In vitro, STAT3 inhibition blunted the ability of OA to restore the expression profiles of autophagy and lipid metabolism in insulin‐resistant liver cells. Collectively, OA may ameliorate T2DM via concomitant STAT3 phosphorylation to modulate hepatic lipid metabolism and autophagy. This study offers novel insights into the mechanisms by which OA treats T2DM, presenting fresh perspectives for T2DM clinical management.
- 15 July 2026
- Published by Wiley in Food Science & Nutrition
- Vol. 14 (7) , e72063
Open AccessOleanolic Acid Ameliorates Hepatic Lipid Metabolism and Autophagy in Type 2 Diabetic Mice via the STAT3 Signaling Pathway
Type 2 diabetes mellitus (T2DM) poses a major global health challenge due to its considerable disability and mortality rates. The complex etiology of T2DM involves hepatic steatosis and autophagy dysfunction. Previous research indicates that oleanolic acid (OA) ameliorates T2DM, with signal transducer and activator of transcription 3 (STAT3) serving as a crucial regulator in numerous cellular processes. Therefore, this study aims to explore whether the therapeutic effects of OA are associated with STAT3 activation and its potential role in hepatic lipid metabolism and autophagy in T2DM. T2DM was induced in mice by feeding a high‐fat diet followed by multiple low‐dose streptozotocin injections. OA notably lowered blood glucose and lipid levels, along with improvements in glucose tolerance and insulin sensitivity. Additionally, OA alleviated liver injury and steatosis. In T2DM mice, OA reduced hepatic protein and gene expression associated with fatty acid uptake/synthesis while enhancing those linked to fatty acid β‐oxidation. Moreover, OA modulated autophagy‐related proteins, as evidenced by increased p62 levels and decreased LC3‐II and Beclin‐1 levels. Molecular docking analysis predicted a potential interaction between OA and STAT3, and Western blot showed increased STAT3 phosphorylation at Y705 after OA treatment . In vitro, STAT3 inhibition blunted the ability of OA to restore the expression profiles of autophagy and lipid metabolism in insulin‐resistant liver cells. Collectively, OA may ameliorate T2DM via concomitant STAT3 phosphorylation to modulate hepatic lipid metabolism and autophagy. This study offers novel insights into the mechanisms by which OA treats T2DM, presenting fresh perspectives for T2DM clinical management.
- 26 March 2026
- Published by Elsevier in Phytomedicine
- Vol. 155, 158091
Duzhong-Gegen formula ameliorated hyperuricemia by enhancing renal uric acid excretion through activation of SIRT1
- 26 March 2026
- Published by Elsevier in Phytomedicine
- Vol. 155, 158091
Duzhong-Gegen formula ameliorated hyperuricemia by enhancing renal uric acid excretion through activation of SIRT1
- 9 October 2025
- Published by Elsevier in Biochemical Pharmacology
- Vol. 242 (Pt 4) , 117408
Roles of an endogenous peptide ELABELA in ameliorating hyperuricemia by inhibiting uric acid production via CYP27A1-modulated bile acid metabolism in mice
- 9 October 2025
- Published by Elsevier in Biochemical Pharmacology
- Vol. 242 (Pt 4) , 117408
Roles of an endogenous peptide ELABELA in ameliorating hyperuricemia by inhibiting uric acid production via CYP27A1-modulated bile acid metabolism in mice
- 16 November 2024
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 254, 116570
Rapid and simple fluorescent detection of chlorogenic acid in Aidi injection using aggregation-induced emission (AIE) nanoclusters
- 16 November 2024
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 254, 116570
Rapid and simple fluorescent detection of chlorogenic acid in Aidi injection using aggregation-induced emission (AIE) nanoclusters
- Open Access
- 15 June 2024
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 177, 116859
Aqueous extract of Phellinus igniarius ameliorates hyperuricemia and renal injury in adenine/potassium oxonate-treated mice
- 15 June 2024
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 177, 116859
Open AccessAqueous extract of Phellinus igniarius ameliorates hyperuricemia and renal injury in adenine/potassium oxonate-treated mice
- Open Access
- 19 April 2022
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 293, 115261
The Chinese medicine Fufang Zhenzhu Tiaozhi capsule protects against atherosclerosis by suppressing EndMT via modulating Akt1/β-catenin signaling pathway
- 19 April 2022
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 293, 115261
Open AccessThe Chinese medicine Fufang Zhenzhu Tiaozhi capsule protects against atherosclerosis by suppressing EndMT via modulating Akt1/β-catenin signaling pathway
- Open Access
- 29 September 2019
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 23 (12) , 8139-8150
Sodium butyrate attenuates angiotensin II‐induced cardiac hypertrophy by inhibiting COX2/PGE2 pathway via a HDAC5/HDAC6‐dependent mechanism
Sodium butyrate (NaBu) is reported to play important roles in a number of chronic diseases. The present work is aimed to investigate the effect of NaBu on angiotensin II (Ang II)‐induced cardiac hypertrophy and the underlying mechanism in in vivo and in vitro models. Sprague Dawley rats were infused with vehicle or Ang II (200 ng/kg/min) and orally administrated with or without NaBu (1 g/kg/d) for two weeks. Cardiac hypertrophy parameters and COX2/PGE2 pathway were analysed by real‐time PCR, ELISA, immunostaining and Western blot. The cardiomyocytes H9C2 cells were used as in vitro model to investigate the role of NaBu (2 mmol/L) in inhibition of Ang II‐induced cardiac hypertrophy. NaBu significantly attenuated Ang II‐induced increase in the mean arterial pressure. Ang II treatment remarkably increased cardiac hypertrophy as indicated by increased ratio of heart weight/body weight and enlarged cardiomyocyte size, extensive fibrosis and inflammation, as well as enhanced expression of hypertrophic markers, whereas hearts from NaBu‐treated rats exhibited a significant reduction in these hypertrophic responses. Mechanistically, NaBu inhibited the expression of COX2/PGE2 along with production of ANP and phosphorylated ERK (pERK) stimulated by Ang II in in vivo and in vitro, which was accompanied by the suppression of HDAC5 and HDAC6 activities. Additionally, knocking down the expression of HDAC5 and HDAC6 via gene‐editing strategy dramatically blocked Ang II‐induced hypertrophic responses through COX2/PGE2 pathway. These results provide solid evidence that NaBu attenuates Ang II‐induced cardiac hypertrophy by inhibiting the activation of COX2/PGE2 pathway in a HDAC5/HDAC6‐dependent manner.
- 29 September 2019
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 23 (12) , 8139-8150
Open AccessSodium butyrate attenuates angiotensin II‐induced cardiac hypertrophy by inhibiting COX2/PGE2 pathway via a HDAC5/HDAC6‐dependent mechanism
Sodium butyrate (NaBu) is reported to play important roles in a number of chronic diseases. The present work is aimed to investigate the effect of NaBu on angiotensin II (Ang II)‐induced cardiac hypertrophy and the underlying mechanism in in vivo and in vitro models. Sprague Dawley rats were infused with vehicle or Ang II (200 ng/kg/min) and orally administrated with or without NaBu (1 g/kg/d) for two weeks. Cardiac hypertrophy parameters and COX2/PGE2 pathway were analysed by real‐time PCR, ELISA, immunostaining and Western blot. The cardiomyocytes H9C2 cells were used as in vitro model to investigate the role of NaBu (2 mmol/L) in inhibition of Ang II‐induced cardiac hypertrophy. NaBu significantly attenuated Ang II‐induced increase in the mean arterial pressure. Ang II treatment remarkably increased cardiac hypertrophy as indicated by increased ratio of heart weight/body weight and enlarged cardiomyocyte size, extensive fibrosis and inflammation, as well as enhanced expression of hypertrophic markers, whereas hearts from NaBu‐treated rats exhibited a significant reduction in these hypertrophic responses. Mechanistically, NaBu inhibited the expression of COX2/PGE2 along with production of ANP and phosphorylated ERK (pERK) stimulated by Ang II in in vivo and in vitro, which was accompanied by the suppression of HDAC5 and HDAC6 activities. Additionally, knocking down the expression of HDAC5 and HDAC6 via gene‐editing strategy dramatically blocked Ang II‐induced hypertrophic responses through COX2/PGE2 pathway. These results provide solid evidence that NaBu attenuates Ang II‐induced cardiac hypertrophy by inhibiting the activation of COX2/PGE2 pathway in a HDAC5/HDAC6‐dependent manner.